TFTiciana De Francesco

Ticiana De Francesco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ticiana De Francesco has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Intermediate outcomes of SIBS microshunt in cases of refractory and nonrefractory glaucoma

    by Edward Tran, Ticiana De Francesco, Anastasiya Vinokurtseva, Matthew B. Schlenker, Iqbal Ike K. Ahmed

  • Open Access

    Peripheral Iris Cerclage in Angle Closure Glaucoma: A Retrospective Pilot Study

    by Ticiana De Francesco, Edward Tran, Fernanda Nicolela Susanna, Iqbal Ike K Ahmed

    Purpose: To describe a novel surgical technique using peripheral iris cerclage (PIC) and evaluate clinical and anatomical outcomes in eyes with angle-closure glaucoma (ACG). Methods: Single-center retrospective pilot study of 8 consecutive eyes (7 patients) with ACG at high risk of recurrence undergoing peripheral iris cerclage (2010– 2025), with adjunctive procedures. Primary outcomes were postoperative Shaffer angle grade and peripheral anterior synechiae (PAS). Secondary outcomes included surgical success, intraocular pressure (IOP), and glaucoma medication use. Surgical success was defined as IOP ≤ 18 mmHg with ≥ 20% reduction from baseline, without clinical hypotony (IOP < 6 mmHg accompanied by ≥ 2-line loss of visual acuity from baseline). Eyes that underwent surgical revision, reoperation or developed no light perception vision were classified as failures. Complete success required no glaucoma medications; qualified success permitted glaucoma medications. Results: Median Shaffer angle grading (interquartile range [IQR]) increased significantly from 0 (0– 0) to 3 (3– 3) (P=0.01), and PAS also significantly decreased in all eyes (P=0.03), with 6 eyes (75%) demonstrating no PAS. Postoperative imaging demonstrated relative thinning of the peripheral iris and widening of the angle. Median IOP decreased from 33.5 (31.2– 43.5) mmHg to 12.0 (10– 15) mmHg (p=0.01) and medication classes decreased from 4 (4– 4) to 2 (1– 3) (p=0.04). Two eyes (25.0%) achieved complete success, while 7 eyes (87.5%) achieved qualified success. No intraoperative complications occurred. One patient required secondary glaucoma surgery. Conclusion: Peripheral iris cerclage was associated with sustained angle widening, favorable PAS outcomes, and substantial IOP reduction in this pilot series. This technique may serve as a useful adjunct in the surgical management of glaucoma, particularly in ACG eyes with flaccid iris tone, a high or thick iris insertion, and risk of recurrent synechiae.

  • The Flip Sides of Interventional Glaucoma

    by Ticiana De Francesco, Angelo P. Tanna, Iqbal Ike K. Ahmed

  • Open Access

    Comparative Outcomes of Standalone Xen63 Gel Stent and Preserflo Microshunt Implantation: A Multicenter Study

    by Ticiana De Francesco, Huixin Anna Zhang, Vital P Costa, Iqbal Ike K Ahmed

    Purpose: To evaluate the intraocular pressure (IOP)-lowering efficacy and adverse event profile of Xen63 gel stent compared to the Preserflo microshunt. Methods: Retrospective, multicenter, two-arm cohort study comparing 65 eyes undergoing standalone Xen63 implantation and 75 eyes undergoing standalone Preserflo implantation, all with intraoperative mitomycin C (MMC). Primary outcome was complete success, defined as all of the followings: 1) no two consecutive IOP readings > 17mmHg, 2) ≥ 20% IOP reduction from baseline; 3) no clinical hypotony (IOP < 6 mmHg associated with loss of ≥ 2 lines of vision); and 4) no use of glaucoma medications. Secondary outcomes included success at different IOP cut offs, qualified success (allowing medications), change in IOP, medications, complications, interventions, and re-operations. Results: At 12 months, complete success was achieved in 61.5% of eyes in the Xen63 group and 73.9% in the Preserflo group (p = 0.13). Postoperative complications were more frequent in the Xen63 group compared with the Preserflo group (61.5% vs. 29.3%, p = 0.0002). Postoperative interventions were required at similar rates between groups (Xen63 30.8% vs. Preserflo 28.0%, p = 0.85); however, reoperations were performed more frequently in the Xen63 group (16.9% vs. 4.0%, p = 0.01). Non-Caucasian ethnicity was associated with an increased risk of surgical failure (HR 2.57; 95% CI, 1.26– 5.23). Conclusion: Both devices achieved comparable success rates, median IOP reduction, and postoperative medication burden; however, the Xen63 group experienced a higher rate of complications and reoperations.

  • Open Access

    A Systematic and Narrative Review of Safety and Complications in Minimally Invasive Glaucoma Surgery (MIGS) Between 2014–2024 [Letter]

    by Zoltan Nagy, Kinga Kranitz, Iqbal Ahmed, Ticiana De Francesco, Eric Mikula, Tibor Juhasz

    Introduction: Earlier intervention in glaucoma has been suggested to slow disease progression and preserve visual function and quality of life. Consequently, minimally invasive glaucoma surgery (MIGS) is increasingly used in mild-to-moderate glaucoma. Although numerous techniques and devices are available, their comparative efficacy remains debated: most procedures lower intraocular pressure to the mid-teens in primary open-angle glaucoma, but without clear evidence of superiority. As these surgeries are now offered to younger, otherwise healthy patients, safety has therefore become a central criterion in technique selection. Methods: This PRISMA-based systematic review analyzed safety outcomes from peer-reviewed studies of the main MIGS procedures published between 2014 and 2024. Five databases were searched using current and historical device names. Non-clinical studies, case series, and nonstandard techniques were excluded from quantitative analysis but retained qualitatively to capture rare events. A total of 401 studies, representing 39,381 eyes and 68,917 eye-years of follow-up, were included. Highest reported and weighted mean complication rates were calculated by procedure type. Results: Safety profiles varied. Trabecular bypass implants and ab interno canaloplasty were associated with low rates of serious adverse events and minimal anatomical disruption. Suprachoroidal devices carried higher risks of hypotony, inflammation, and malposition. Across all categories, chronic changes to angle anatomy and occasionnal re-interventions highlighted the potential for long-term sequelae, with endothelial cell loss emerging as a key concern for certain procedures.However, heterogeneity in definitions and reporting limited comparability. Common events such as hyphema and IOP spikes were inconsistently documented, while late complications like endothelial cell loss or peripheral anterior synechiae were often overlooked. This underreporting risks conflicting conclusions and undermines comparisons. Conclusion: For patients with mild, stable disease or those undergoing opportunistic combined surgery, tissue-sparing procedures with the lowest observed complication rates may be preferable. Standardized definitions, long-term follow-up, and harmonized safety reporting are becoming essential.


  • Open Access

    Intermediate Outcomes of a Novel Flat Glaucoma Drainage Device in Uncontrolled Primary Open Angle Glaucoma

    by Ticiana De Francesco, Mariela Gómez Mejía, Iqbal Ahmed, Mario Miranda Velásquez

    To evaluate the intraocular pressure (IOP) lowering effect and adverse event profile of the Implante Plano Miranda (IPM), a novel flat glaucoma drainage device. Prospective, single-arm, open-label Phase II clinical trial including 24 eyes with uncontrolled primary open-angle glaucoma (POAG) despite maximal tolerated medical therapy, undergoing standalone IPM implantation with adjunctive Mitomycin-C (MMC). Primary outcome was the proportion of eyes achieving surgical success, defined by: ≥ 20% IOP reduction from baseline on same or fewer medications without clinical hypotony or reoperation. Secondary outcomes included changes in IOP, medication burden, endothelial cell density (ECD), and adverse events. Patients were followed for 12 months. At 12 months, surgical success was achieved in 79.5% of eyes. Median IOP decreased from 24.0 mmHg (IQR 24–26) preoperatively to 14.0 mmHg (IQR 12–17) at one year (p < 0.0001), representing a 41.6% reduction. Median glaucoma medications decreased from 4 (IQR 3–4) to 1 (IQR 0–3) (p < 0.0001). ECD remained stable (baseline 1,671.98 ± 570.75 vs. 12 months 1,684.37 ± 549.25 cells/mm2; p = 0.797). Minor adverse events occurred in 29.1% of eyes; no serious complications or reoperations were reported. The IPM was associated with significant IOP reduction and decreased medication use at one year. No serious safety events were observed during the 12-month follow-up. Given the small sample size and single-arm design, larger controlled studies with longer follow-up are necessary to better define the safety and efficacy profile of this device.

  • Open Access

    One-year outcomes of an ab externo sibs microshunt in combination with phacoemulsification

    by Edward Tran, Ticiana De Francesco, Jingyi Ma, Matthew B. Schlenker, Iqbal Ike K. Ahmed

  • A Large-Scale Cohort Analysis of Topical Prostaglandin Analog Use and Pseudophakic Cystoid Macular Edema Following Cataract Surgery

    by Jawad Muayad, Ali O. Mukhtar, Darius D. Bordbar, Asad Loya, Amer F. Alsoudi, Christina Y. Weng, Ticiana De Francesco, Iqbal Ike K. Ahmed


  • Glaucoma Surgery Comparison: SIBS Microshunt Versus Gelatin 45 µm Microstent Versus Trabeculectomy as Primary Surgical Interventions

    by James J. Armstrong, Ticiana De Francesco, Henny J. Beckers, Ingeborg Stalmans, Antonio M. Fea, Chelvin C.A. Sng, Juan F. Batlle Sr, Matthew B. Schlenker, Iqbal Ike K. Ahmed